ReachMD CME

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B...

CME credits: 1.00 Valid until: 26-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/ Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don’t miss this opportun...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37676/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37675/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37674/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37673/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37672/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37671/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/37670/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/tbd/36194/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (R...

CME credits: 1.00 Valid until: 24-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-critical-interplay-ckd-hf-and-hyperkalemia/36193/ Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–a...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/ Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn t...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-directions-in-fsgs-care/37191/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. B...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-the-patient-voice-in-fsgs-management/37190/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals fo...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-considerations-for-pediatric-patients-with-fsgs/37189/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatme...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-fsgs-traditional-and-novel-biomarkers/37187/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals fo...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therap...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-interpretation-of-proteinuria-reduction-thresholds/37185/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment g...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-fsgs-treatment-landscape-more-questions-than-answers/37184/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatm...

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-when-solutions-fall-short/37183/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. B...

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Real-World-Evidence-of-Photobiomodulation-Efficacy-in-Ocular-Indications/35952/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists a...

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Integration-of-Photobiomodulation-Therapy-into-the-Age-Related-Macular-Degeneration-Treatment-Landscape/35951/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading resea...

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Patient-Centered-Care-and-Integration-of-Photobiomodulation-Therapy-into-Clinical-Practice/35950/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and re...

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Best-Practices-for-Optimized-Photobiomodulation-Treatment-Effect-Candidate-Selection/35949/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina s...